Ipzz-137 «2025-2027»

A companion diagnostic based on quantitative PCR for MYC amplification and a transcriptional MYC‑signature assay (Nanostring or RT‑qPCR panel) is being co‑developed. Early data suggest a threshold of ≥4‑fold MYC copy number or a signature score >1.5 predicts ≥70 % probability of response.

In murine sub‑cutaneous xenografts of Daudi lymphoma, oral IPZZ‑137 (30 mg/kg once daily) achieved tumor growth inhibition (TGI) of 92 % after 21 days, with complete regression in 3 of 8 mice. Pharmacodynamic (PD) biomarkers—decreased Ki‑67 staining and reduced MYC‑MAX co‑immunoprecipitation—correlated with drug exposure. No significant weight loss or hematologic toxicity was observed. ipzz-137

“We’re standing at the threshold where quantum and classical worlds finally speak the same language,” reflects , VP of Engineering at QuantumPulse Labs. “IPZZ‑137 is that translator.” A companion diagnostic based on quantitative PCR for

IPZZ‑137 is the flagship product of , a Silicon Valley spin‑out that emerged from the 2022 DARPA “Quantum‑AI Accelerator” program. It is the first commercially‑available processor that natively merges a dense classical ASIC core with a 256‑qubit superconducting quantum array , all on a single monolithic package. “IPZZ‑137 is that translator

IPZZ‑137 stands as a compelling example of how a disciplined, target‑focused screening campaign can convert an “undruggable” protein–protein interaction into a tractable therapeutic opportunity. Its journey—from an initial hit in a phenotypic assay to a pre‑clinical candidate with robust in‑vivo efficacy—highlights the synergy between modern medicinal chemistry, structural biology, and translational oncology. While challenges remain—particularly around resistance, safety, and regulatory pathways—the strategic biomarker‑driven development plan positions IPZZ‑137 to fulfill the promise of precision medicine for patients whose cancers are driven by the notorious MYC oncogene. If forthcoming clinical trials validate its pre‑clinical promise, IPZZ‑137 could inaugurate a new class of selective PPI modulators that extend far beyond MYC, reshaping the therapeutic landscape for a host of diseases previously deemed “undruggable.”